Journal article

Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants

Nasim Mavaddat, Paul DP Pharoah, Kyriaki Michailidou, Jonathan Tyrer, Mark N Brook, Manjeet K Bolla, Qin Wang, Joe Dennis, Alison M Dunning, Mitul Shah, Robert Luben, Judith Brown, Stig E Bojesen, Borge G Nordestgaard, Sune F Nielsen, Henrik Flyger, Kamila Czene, Hatef Darabi, Mikael Eriksson, Julian Peto Show all

JNCI: Journal of the National Cancer Institute | OXFORD UNIV PRESS INC | Published : 2015

Grants

Awarded by Cancer Research-UK


Awarded by European Community


Awarded by European Union


Awarded by Ministry of Economic Development, Innovation and Export Trade of Quebec


Awarded by National Institutes of Health Post-Genome Wide Association initiative


Awarded by European Union European Cooperation in Science and Technology (COST) programme


Awarded by US National Cancer Institute


Awarded by Dutch Cancer Society


Awarded by BBMRI-NL - Dutch government


Awarded by Fondo de Investigacion Sanitario


Awarded by California Breast Cancer Research Fund


Awarded by National Institutes of Health


Awarded by Lon V. Smith Foundation


Awarded by Against Breast Cancer Registered Charity


Awarded by charity Against Breast Cancer


Awarded by US Military Acquisition (ACQ) Activity, an Era of Hope Award


Awarded by Deutsche Krebshilfe


Awarded by Federal Ministry of Education and Research (BMBF) Germany


Awarded by Deutsche Krebshilfe e. V.


Awarded by Academy of Finland


Awarded by German Federal Ministry of Research and Education


Awarded by Ministry of Education and Science of the Russian Federation


Awarded by Russian Foundation for Basic Research


Awarded by State task of the Ministry of Education and Science of the Russian Federation


Awarded by National Health and Medical Research Council


Awarded by United States Army Medical Research and Materiel Command


Awarded by Stichting tegen Kanker


Awarded by Deutsche Krebshilfe e.V.


Awarded by Italian citizens of the Fondazione IRCCS Istituto Nazionale Tumori


Awarded by National Institutes of Health, a National Institutes of Health Specialized Program of Research Excellence (SPORE) in Breast Cancer


Awarded by Australian National Health and Medical Research Council


Awarded by Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program


Awarded by Ministry of Economic Development, Innovation and Export Trade


Awarded by Norwegian Research council


Awarded by Genetic Associations and Mechanisms in Oncology (GAME-ON) Network


Awarded by Biobanking and Biomolecular Resources Research Infrastructure


Awarded by Cancer Risk Prediction Center, a Linneus Centre - Swedish Research Council


Awarded by Yorkshire Cancer Research


Awarded by National Institutes of Health Specialized Program of Research Excellence in Breast Cancer


Awarded by Hellenic Cooperative Oncology Group


Awarded by RPCI DataBank and BioRepository (DBBR), a Cancer Center Support Grant Shared Resource


Awarded by National Institutes of Health, National Cancer Institute


Awarded by Lon V Smith Foundation


Awarded by Massachusetts center


Awarded by Wisconsin center


Awarded by New Hampshire center


Awarded by Vanderbilt-Ingram Cancer Center



Funding Acknowledgements

This work was supported by Cancer Research-UK (grant numbers C1287/A10118, C1287/A12014) and the European Community's Seventh Framework Programme (223175 [HEALTH-F2-2009-223175]) (COGS). Genotyping of the iCOGS array was funded by the European Union (HEALTH-F2-2009-223175), Cancer Research UK (C1287/A10710), the Canadian Institutes of Health Research (CIHR) for the "CIHR Team in Familial Risks of Breast Cancer" program, and the Ministry of Economic Development, Innovation and Export Trade of Quebec (PSR-SIIRI-701). This work was also supported by Breakthrough Breast Cancer funding (to MGC). Analysis was supported in part by the National Institutes of Health Post-Genome Wide Association initiative (1U19CA148065 (DRIVE) and 1U19CA148537 (ELLIPSE)). Laboratory infrastructure was funded by Cancer Research UK (C8197/A10123). This work was also supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research and the Ministere de l'enseignement superieur, de la recherche, de la science et de la technologie du Quebec through Genome Quebec for the PERSPECTIVE project. Breast Cancer Association Consortium meetings were funded by the European Union European Cooperation in Science and Technology (COST) programme (BM0606).The Australian Breast Cancer Family Study (ABCFS), Northern California Breast Cancer Family Registry (NC-BCFR) and Ontario Familial Breast Cancer Registry (OFBCR) studies were supported by the US National Cancer Institute (UM1 CA164920). The ABCFS was also supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation (Australia), and the Victorian Breast Cancer Research Consortium. JLH is a National Health and Medical Research Council (NHMRC) Australia Fellow and a Victorian Breast Cancer Research Consortium Group Leader. MCS is an NHMRC Senior Research Fellow and a Victorian Breast Cancer Research Consortium Group Leader. JLH and MCS are both group leaders of the Victoria Breast Cancer Research Consortium. The content of this manuscript does not necessarily reflect the views or policies of the US National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR.The Amsterdam Breast Cancer Study (ABCS) was supported by the Dutch Cancer Society (NKI 2007-3839; 2009 4363) and BBMRI-NL, which is a Research Infrastructure financed by the Dutch government (NWO 184.021.007).The Australian Breast Cancer Tissue Bank (ABCTB) study was supported by the National Health and Medical Research Council of Australia, The Cancer Institute New South Wales and the National Breast Cancer Foundation.The Bavarian Breast Cancer Cases and Controls (BBCC) study was partly funded by ELAN-Fond of the University Hospital of Erlangen.The British Breast Cancer Study (BBCS) was funded by Cancer Research UK and Breakthrough Breast Cancer and acknowledges National Health Service funding to the National Institutes for Health Research Biomedical Research Centre, and the National Cancer Research Network (NCRN). The BBCS GWAS received funding from The Institut National de Cancer.The Breast Cancer In Galway Genetic Study (BIGGS) was supported by National Institutes for Health Research Comprehensive Biomedical Research Centre, Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London, United Kingdom (ES), and the Oxford Biomedical Research Centre (IT).The Breast Cancer Study of the University Clinic Heidelberg (BSUCH) was supported by the Dietmar-Hopp Foundation, the Helmholtz Society, and the German Cancer Research Center (DKFZ).The CECILE Breast Cancer Study (CECILE) was funded by Fondation de France, Institut National du Cancer (INCa), Ligue Nationale contre le Cancer, Ligue contre le Cancer Grand Ouest, Agence Nationale de Securite Sanitaire (ANSES), Agence Nationale de la Recherche (ANR).The Copenhagen General Population Study (CGPS) was supported by the Chief Physician Johan Boserup and Lise Boserup Fund, the Danish Medical Research Council, and Herlev Hospital.The Spanish National Cancer Centre Breast Cancer Study (CNIO-BCS) was supported by the Genome Spain Foundation, the Red Tematica de Investigacion Cooperativa en Cancer, and by grants from the Asociacion Espanola Contra el Cancer and the Fondo de Investigacion Sanitario (PI11/00923, PI081120).The California Teachers Study (CTS) was initially supported by the California Breast Cancer Act of 1993 and the California Breast Cancer Research Fund (contract 97-10500) and is currently funded through the National Institutes of Health (R01 CA77398). The CTS study was also funded by the Lon V. Smith Foundation (LVS39420) to HAC. Collection of cancer incidence data was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885.For the DietCompLyf Breast Cancer Survival Study (DBCSS) the University of Westminster curated the DietCompLyf database, created by and funded by Against Breast Cancer Registered Charity No. 1121258. The University of Westminster's Against Breast Cancer Research Unit acknowledges funding from the charity Against Breast Cancer (Registered Charity Number 1121258).The Esther Breast Cancer Study (ESTHER) was supported by a grant from the Baden Wurttemberg Ministry of Science, Research and Arts. Additional cases were recruited in the context of the VERDI study, which was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe).The Familial Breast Cancer Study (FBCS) study was supported by funds from Cancer Research UK (C8620/A8372, C8620/A8857), a US Military Acquisition (ACQ) Activity, an Era of Hope Award (W81XWH-05-1-0204), and the Institute of Cancer Research UK. CT is funded by a Medical Research Council (UK) Clinical Research Fellowship. The FBCS acknowledges National Health Service (NHS) funding to the Royal Marsden / Institute of Cancer Research National Institutes for Health Research (NIHR) Specialist Cancer Biomedical Research Centre.The German Consortium for Hereditary Breast & Ovarian Cancer (GC-HBOC) was supported by Deutsche Krebshilfe (107 352).Gene Environment Interaction and Breast Cancer in Germany (GENICA) was funded by the Federal Ministry of Education and Research (BMBF) Germany (01KW9975/5, 01KW9976/8, 01KW9977/0, 01KW0114), the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, and the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany.The Genetic Epidemiology Study of Breast Cancer by Age 50 (GESBC) study was supported by the Deutsche Krebshilfe e. V. (70492) and the German Cancer Research Center (DKFZ).The Hannover Breast Cancer Study (HABCS) was supported by an intramural grant from Hannover Medical School.The Helsinki Breast Cancer Study (HEBCS) was financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (grant number 266528), the Finnish Cancer Society, the Nordic Cancer Union, and the Sigrid Juselius Foundation.The Hannover-Minsk Breast Cancer Study (HMBCS) was supported by a grant from the Friends of Hannover Medical School and by the Rudolf Bartling Foundation.The Hannover-Ufa Breast Cancer Study (HUBCS) was supported by a grant from the German Federal Ministry of Research and Education (RUS08/017) and by the Ministry of Education and Science of the Russian Federation (number 14.574.21.0026, agreement dated June 17, 2014, a unique identifier agreement RFMEFI57414X0026), the Russian Foundation for Basic Research (14-04-31169 mol_a) and State task of the Ministry of Education and Science of the Russian Federation (310-14).The Karolinska Breast Cancer Study (KARBAC) was supported by the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, the Swedish Cancer Society, the Gustav V. Jubilee foundation, and the Bert von Kantzows foundation.The Kuopio Breast Cancer Project (KBCP) was supported by the special Government Funding (EVO) of Kuopio University Hospital grants, Cancer Fund of North Savo, the Finnish Cancer Organizations, the Academy of Finland, and by the strategic funding of the University of Eastern Finland.The kConFab study was supported by the National Breast Cancer Foundation and previously by the National Health and Medical Research Council, the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, and the Cancer Foundation of Western Australia. The kConFab Clinical Follow Up Study was funded by the National Health and Medical Research Council (145684, 288704, 454508). RB was a Cancer Institute NSW Fellow.The AOCS study was supported by the United States Army Medical Research and Materiel Command (DAMD17-01-1-0729), the Cancer Council of Tasmania, the Cancer Foundation of Western Australia and the National Health and Medical Research Council (199600), and a National Health and Medical Research Council grant to GCT.The Leuven Multidisciplinary Breast Centre (LMBC) study is supported by the "Stichting tegen Kanker" (232-2008, 196-2010) and by the FWO and the KULPFV/10/016-SymBioSysII to DL.The Mammary Carcinoma Risk Factor Investigation (MARIE) study was supported by the Deutsche Krebshilfe e.V. (70-2892-BR I, 106332, 108253, 108419), the Hamburg Cancer Society, the German Cancer Research Center (DKFZ), and the Federal Ministry of Education and Research (BMBF) Germany (01KH0402).The Milan Breast Cancer Study Group (MBCSG) was supported by grants from the Italian Association for Cancer Research (AIRC) and by funds from the Italian citizens who allocated the 5/1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects "5x1000").The Mayo Clinic Breast Cancer Study (MCBCS) was supported by the National Institutes of Health (CA122340, CA128978), a National Institutes of Health Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), the Breast Cancer Research Foundation, the Komen Race for the Cure, and by a generous gift from the David F. and Margaret T. Grohne Family Foundation and the Ting Tsung and Wei Fong Chao Foundation.The Melbourne Collaborative Cohort Study (MCCS) cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian National Health and Medical Research Council (209057, 251553, 504711) and by infrastructure provided by Cancer Council Victoria.The Multi-ethnic Cohort (MEC) was supported by the National Institutes of Health (CA63464, CA54281, CA098758, and CA132839).The Memorial Sloan-Kettering Cancer Center (MSKCC) was supported by grants from the Breast Cancer Research Foundation and the Robert and Kate Niehaus Clinical Cancer Genetics Initiative.The work of Montreal Gene-Environment Breast Cancer Study (MTLGEBCS) was supported by the Quebec Breast Cancer Foundation, the Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program (CRN-87521), and the Ministry of Economic Development, Innovation and Export Trade (PSR-SIIRI-701). MG received an Investigator Award from the CIHR and a Health Scholar Award from the Fonds de la recherche en sante du Quebec. J Simard is chairholder of the Canada Research Chair in Oncogenetics.The Norwegian Breast Cancer Study (NBCS) was supported by grants from the Norwegian Research council (155218/V40, 175240/S10 to ALBD, FUGE-NFR 181600/V11) to VNK and a Swizz Bridge Award to ALBD.The Nashville Breast Health Study (NBHS) was supported by National Institutes of Health (grant R01CA100374).The Nurses Health Study (NHS) was funded by National Institutes of Health (PO1 CA87969), and this project was (in part) supported by the Genetic Associations and Mechanisms in Oncology (GAME-ON) Network (U19 CA148065).The Oulu Breast Cancer Study (OBCS) was supported by research grants from the Finnish Cancer Foundation, the Academy of Finland, the University of Oulu, and the Oulu University Hospital.The Leiden University Medical Centre Breast Cancer Study (ORIGO) was supported by the Dutch Cancer Society (RUL 1997-1505) and the Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL CP16).The NCI Polish Breast Cancer Study (PBCS) was supported by the Intramural Research Programs of the Division of Cancer Epidemiology and Genetics and the Center for Cancer Research of the National Cancer Institute.The Karolinska Mammography Project for Risk Prediction of Breast Cancer (pKARMA) study was supported by Marit and Hans Rausings Initiative Against Breast Cancer and Cancer Risk Prediction Center, a Linneus Centre (contract 70867902) financed by the Swedish Research Council.The Prospective Study of Outcomes in Sporadic Versus Hereditary Breast Cancer (POSH) study was supported by Cancer Research UK (A7572, A11699, C22524).The Rotterdam Breast Cancer Study (RBCS) was funded by the Dutch Cancer Society (DDHK 2004-3124, DDHK 2009-4318).The Singapore and Sweden Breast Cancer Study (SASBAC) was supported by the Agency for Science, Technology and Research of Singapore (A*STAR), the National Institutes of Health, and the Susan G. Komen Breast Cancer Foundation.The Sheffield Breast Cancer Study (SBCS) was supported by Yorkshire Cancer Research (S295, S299, S305PA) and the Sheffield Experimental Cancer Medicine Centre.The Southern Community Cohort Study (SCCS) is funded by National Institutes of Health (R01 CA092447). The Arkansas Central Cancer Registry is fully funded by a grant from the National Program of Cancer Registries, Centers for Disease Control and Prevention (CDC).Study of Epidemiology and Risk factors in Cancer Heredity (SEARCH) was funded by a programme grant from Cancer Research UK (C490/A10124), the UK National Institute for Health Research Biomedical Research Centre at the University of Cambridge, and a Cancer Research UK grant (C8197/A10123) to AMD.The Stadtisches Klinikum Karlsruhe Deutsches Krebsforschungszentrum Study (SKKDKFZS) was supported by the Deutsches Krebsforschungszentrum (DKFZ).The IHCC-Szczecin Breast Cancer Study (SZBCS) was supported by grant (PBZ_KBN_122/P05/2004).The Triple Negative Breast Cancer Consortium Study (TNBCC) was supported by the National Institutes of Health (CA128978) and the National Institutes of Health Specialized Program of Research Excellence in Breast Cancer (CA116201), the Breast Cancer Research Foundation, a generous gift from the David F. and Margaret T. Grohne Family Foundation and the Ting Tsung and Wei Fong Chao Foundation, the Stefanie Spielman Breast Cancer fund and the Ohio State University (OSU) Comprehensive Cancer Center, DBBR (a CCSG Share Resource by National Institutes of Health Grant P30 CA016056), the European Union (European Social Fund - ESF) and Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF) - Research Funding Program of the General Secretariat for Research & Technology: ARISTEIA.The DEMOKRITOS study was supported by a Hellenic Cooperative Oncology Group research grant (HR R_BG/04) and the Greek General Secretary for Research and Technology (GSRT) Program, Research Excellence II, funded at 75% by the European Union.The OSU study was funded by the Stefanie Spielman fund and the OSU Comprehensive Cancer Center.The Roswell Park Cancer Institute (RPCI) study was supported by RPCI DataBank and BioRepository (DBBR), a Cancer Center Support Grant Shared Resource (P30 CA016056-32).The UCIBCS was supported by the National Institutes of Health, National Cancer Institute grant CA-58860 and the Lon V Smith Foundation grant LVS-39420.The UK Breakthrough Generations Study (UKBGS) was funded by Breakthrough Breast Cancer and the Institute of Cancer Research (ICR). ICR acknowledges NHS funding to the Royal Marsden Hospital/ICR National Institutes for Health Research Biomedical Research Centre.The US Three State Study (US3SS) was supported by Massachusetts (R01CA47305 to KME), Wisconsin (R01 CA47147 to PAN), and New Hampshire (R01CA69664 to LTE) centers and Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services.The US Radiologic Technologists Study (USRT) was funded by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, US Department of Health and Human Services.Biological sample preparation for several studies was conducted at the Epidemiology Biospecimen Core Lab, supported in part by the Vanderbilt-Ingram Cancer Center (P30 CA68485).